DYRK1A and Dravet syndrome: Because of its high affinity for DYRK1A and its impact on osteoblasts and osteoclasts, CX-4945 may be an excellent candidate to treat skeletal abnormalities associated with DS, especially at times when Dyrk1a is overexpressed.